IPHA Innate Pharma SA: Enterprise Value-to-Revenue Multiple

Public company logo of innate-pharma.com (IPHA)

The leadership stability of Innate Pharma S.A. (IPHA) appears debatable until the EV/Sales ratio demonstrates the valuation-to-sales dynamics. The value 23406.88 reflects the latest metric reading, confirming the effectiveness of the model of transferring patents to tech giants in exchange for royalties. The company's strong position is bolstered by its status as a European expert in NK cells, which guarantees the high value of its innovative developments in immuno-oncology.

Company Value to Revenue: Innate Pharma SA (IPHA) for 11/23/2025 - 11/20/2026

innate-pharma.com - analytical breakdowns and key metrics (IPHA)

- share price and consensus valuation forecast:
Initial company analysis:Innate Pharma S.A. IPHA
Product sample of Innate Pharma S.A.

The EV/Sales multiple compares the total enterprise value of a business with its revenue, eliminating the impact of debt load on the valuation. Investors utilize this metric to identify overbought assets and prevent losses during coefficient corrections. Analyzing the historical EV/Sales trend captures the market's reaction to fundamental changes. For Innate Pharma S.A. (IPHA), a high valuation is justified by the prestige of the European scientific school. The intellectual capital of this oncology biotech firm generates the company's long-term value.

Competitor analysis for Innate Pharma S.A.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP